Solesence Inc (SLSN)

Gross Margin Expansion Highlights Solésence’s Operational Restructuring Efforts (SLSN)May 12, 2026 11:06 AM
IH Market News Solésence reported improved gross margin in the first quarter despite lower revenue and a return to a net loss, as the company continued executing its Transform & Transcend strategic initiative. Key Investor Takeaways Solésence (NASDAQ:SLSN) posted first-quarter revenue of $13.0 million, down from $14.6 million a year earlier. Gross margin improved to 26% from 23%, signaling early impact from operational efficiency initiatives. The company reported a net loss of approximately $0.8 million versus net income in the prior-year quarter. Management said restructuring and employee training investments pressured near-term profitability but may improve long-term efficiency. New platform technologies including WHSPR and Chromalüm could support future product commercialization and market expansion. Why SLSN Stock Is in Focus Solésence (NASDAQ:SLSN) released first-quarter 2026 results showing lower sales but improving margins as the company advanced a broader operational restructuring strategy.Revenue for the quarter declined to $13.0 million from $14.6 million in the same period last year.Gross profit was relatively stable at $3.3 million compared with $3.4 million a year ago, while gross margin improved to 26% from 23%.The company also reported a net loss of approximately $0.8 million, compared with net income of roughly $0.08 million in the prior-year quarter.Management attributed the margin improvement to operational efficiency efforts tied to the company’s Transform & Transcend initiative, which was introduced to investors earlier this year.“In March, we introduced Transform and Transcend to our investor community, the strategic initiative that we began at the end of 2025,” said Kevin Cureton. Operational Changes and New Technologies Become Key Focus Solésence said first-quarter investments centered on employee training, organizational restructuring and operational infrastructure improvements.According to CFO Laura Riffner, those investments created short-term pressure on profitability but also reduced labor costs and improved operational efficiency.The company also highlighted commercialization progress tied to its WHSPR and Chromalüm platform technologies, which expanded its over-the-counter product claims portfolio.Additionally, Solésence announced the appointment of financial executive Marc James as a new independent director. Why This Matters for Investors The quarter may signal that Solésence is prioritizing operational restructuring and margin improvement over near-term revenue growth.While declining revenue and the return to a net loss could pressure investor sentiment in the short term, the improvement in gross margin suggests the company’s efficiency initiatives may already be having an impact.Management’s comments also indicate that Solésence is attempting to broaden its addressable market and capture more value across the product development chain through intellectual property and platform commercialization.For investors, the key question may be whether margin gains can continue while revenue growth stabilizes in future quarters.The company’s focus on operational discipline and proprietary product technologies could shape its long-term profitability narrative if execution improves throughout 2026. What To Watch Next Investors will likely monitor whether Solésence can sustain margin expansion while returning to revenue growth in upcoming quarters.Updates related to commercialization of WHSPR and Chromalüm technologies, operational restructuring progress, and profitability trends may remain important catalysts for SLSN stock.Management commentary during the company’s first-quarter conference call may also provide additional detail on growth strategy and expected financial improvements later in the year.Solésence stock price Original: Gross Margin Expansion Highlights Solésence’s Operational Restructuring Efforts (SLSN)

SLSN...$2.21...🥳...Looking for the $2.85 range gap to fill... https://schrts.co/SpDptSiB

Up up up since listing on Nasdaq

$SLSN: Used to be $NANX before Nasdaq UPLIST

Now uplisted to the Nasdaq from the OTC.

Dropped down a bit here to $2.15 now.

Watching for a nice juicy price entry.


https://solesence.com/

https://ir.solesence.com/news-releases/news-release-details/solesence-announces-uplisting-nasdaq

Doing about $52Milly in annual Revenues based out of Illinois....... not bad at all.



GO $SLSN


**************************************************************************************

Solésence Reports Record Fourth Quarter and Full-Year 2024 Financial Results
March 26, 2025
PDF Version
Fourth quarter revenue increased 58% to a record $12.6 million

Full Year 2024 revenue increased 40% to a record $52.3 million

ROMEOVILLE, Ill., March 26, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the fourth quarter and year ended December 31, 2024.

Recent Highlights and Accomplishments

Company rebranded as Solésence, Inc., marking a new era of innovation, self-expression, and inclusivity in skin health. The move reflects the success of its consumer products strategy, fueled by its suite of transformative skin health technologies, including award-winning Kleair™.
Solésence launched a new investor relations website designed to provide current and prospective investors with streamlined access to financial reports, historical disclosures, leadership profiles, and key company updates.
Au Lait Face Milk SPF 50+ featuring Solésence Kleair™ technology was named winner in the best prestige finished formula category at the 2025 Cosmetics & Toiletries (C&T) Alle Awards.
“We are very pleased to report record revenue for both the fourth quarter and full year 2024,” said Jess Jankowski, President, Chief Executive Officer, and Chief Financial Officer of Solésence. “Our strong fourth-quarter results were driven by a shift in customer mix and the timing of key product launches, which, unlike previous years, occurred in the fourth quarter rather than the first. This performance highlights the strength of our customer partnerships and the increasing demand for our innovative skin health solutions.

“We are incredibly proud to report a 40% increase in annual revenue over the prior year. This achievement is a testament to the hard work and dedication of our employees, whose efforts enabled us to meet increased customer demand and contributed to our positive operating cash flow,” said Kevin Cureton, Chief Operating Officer. “As we carry this momentum into 2025, we continue to make meaningful investments in operations, R&D, and our team, positioning us to scale for long-term growth.”

“Given the success of our commercial strategy and the related growth, the Company has decided to pursue an uplisting to the NASDAQ market in 2025, subject to eligibility. As part of this effort and additional related requirements we are anticipating, we also are beginning the search for a dedicated Chief Financial Officer,” said Mr. Jankowski.

Summary Fourth Quarter 2024 Financial Results

Fourth Quarter Financial Highlights

Revenue for the fourth quarter increased 57.5% to a record $12.6 million, compared to $8.0 million for the same period in 2024.
Gross profit increased 460% in the fourth quarter to a record $2.8 million, compared to $0.5 million for the same period in 2023.
Gross margin in the fourth quarter was 22%, compared to 6% for the same period in 2023.
Net loss for the fourth quarter was $0.6 million, compared to a net loss of $2.1 million for the same period in 2023.
Summary Full Year 2024 Financial Results

Revenue for the twelve months ended December 31, 2024, was a record $52.3 million compared to $37.3 million, a 40% increase over the same period in 2023.
Gross profit for the twelve months ended December 31, 2024, was $16.2 million, compared to $7.8 million, a 107% increase over the same period in 2023.
Gross margin for the twelve months ended December 31, 2024, was 31%, compared to 21% for the same period in 2023.
Net income for the twelve months ended December 31, 2024, was $4.2 million, compared to a net loss of $4.4 million in the same period in 2023.
Operational Highlights

Initiated expanded batch-making capabilities at our Bolingbrook facility, adding infrastructure for six production suites and increasing capacity to support over $200 million in annual revenue from the consumer products line.
Produced twice the unit volume in the fourth quarter of 2024 compared to the fourth quarter of 2023.
Launched over two dozen new SKUs across prestige and mass beauty categories, including a new EU-focused brand.
Conference Call

Solésence will host its fourth quarter conference call on Thursday, March 27, 2025, at 7:00 a.m. CDT, 8:00 a.m. EDT, to discuss its financial results and provide a business and financial update. On the call will be Jess Jankowski, President, CEO, and CFO, and Kevin Cureton, Chief Operating Officer.

Webcast Link: https://edge.media-server.com/mmc/p/5vfh7m2x

Dial-In Link: https://register-conf.media-server.com/register/BIcd1760ffa58444b1967f8887796d1b08

To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the option to have the system dial-out to you once the conference call begins. If you forget your PIN prior to the conference call, you can simply re-register.

The call may also be accessed through the company’s investor relations website, at https://ir.solesence.com/. Please join the conference call at least five minutes before prior to the start time.

FINANCIAL RESULTS AND NON-GAAP INFORMATION

Use of Non-GAAP Financial Information

Solésence believes that the presentation of results excluding certain items, such as non-cash equity compensation charges, provides meaningful supplemental information to both management and investors, facilitating the evaluation of performance across reporting periods. The Company uses these non-GAAP measures for internal planning and reporting purposes. These non-GAAP measures are not in accordance with, or an alternative for, Generally Accepted Accounting Principles (“GAAP”) and may be different from non-GAAP measures used by other companies. The presentation of this additional information is not meant to be considered in isolation or as a substitute for net income or net income per share prepared in accordance with GAAP.

About Solésence, Inc.

Solésence, Inc. (OTCQB: NANX), is a leader in scientifically-driven health care solutions across beauty and life science categories. With a mission to deliver joy through innovation, inclusivity and the science of beautiful skin, we have redefined mineral-based sun protection by maximizing transparency, effectiveness, aesthetics, and wearability — empowering individuals to embrace beauty on their own terms. Combining best-in-class skin health solutions with the celebration of self-care, we allow brands to deliver unique product claims and attributes by seamlessly integrating protection, prevention, and treatment technologies into daily use products. Learn more at solesence.com.

Forward-Looking Statements

This press release contains words such as “expects,” “shall,” “will,” “believes,” and similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company’s current beliefs, known events and circumstances at the time of publication, and as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company’s results of operations, performance, and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, without limitation, the following: a decision by a customer to cancel a purchase order or supply agreement in light of the Company’s dependence on a limited number of key customers; uncertain demand for, and acceptance of, the Company’s engineered materials, ingredients, and fully formulated products; the Company’s manufacturing capacity and product mix flexibility in light of customer demand; the Company’s limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company’s dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; the impact of any potential new government regulations that could be difficult to respond to or too costly to comply with while remaining financially viable; the ability of the Company to maintain an appropriate electronic trading venue; and other factors described in the Company’s Form 10-K filed March 28, 2024. In addition, the Company’s forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, or other contingencies. ?

Media Contact:
media@solesence.com

Investor Relations Contact:
investors@solesence.com
(630) 771-6736